
Frazier Life Sciences Management, L.P.
About Frazier Life Sciences Management, L.P.’s 13F portfolio
Frazier Life Sciences Management, L.P. is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Frazier Life Sciences Management, L.P. reported $4.6B across 41 US-listed positions (). Its largest position is MIRUM PHARMACEUTICALS INC (MIRM) at 20% of the reported book, and its ten biggest holdings make up 74% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: MIRM MIRUM PHARMACEUTICALS INC | — — | 20% | 7.7M | $899.1M |
| 2 | NASDAQ: NAMS NEWAMSTERDAM PHARMA COMPANY | — — | 13% | 18.1M | $613.0M |
| 3 | NASDAQ: ERAS ERASCA INC | — — | 10.0% | 25.0M | $457.5M |
| 4 | NASDAQ: MBX MBX BIOSCIENCES INC | — — | 8.0% | 6.7M | $367.2M |
| 5 | NASDAQ: ARQT ARCUTIS BIOTHERAPEUTICS INC | — — | 5.6% | 9.9M | $258.9M |
| 6 | NASDAQ: TRVI TREVI THERAPEUTICS INC | — — | 4.0% | 9.9M | $185.4M |
| 7 | NASDAQ: KRYS KRYSTAL BIOTECH INC | — — | 3.9% | 481K | $178.9M |
| 8 | NASDAQ: MAZE MAZE THERAPEUTICS INC | — — | 3.3% | 5.0M | $150.2M |
| 9 | NASDAQ: PHAT PHATHOM PHARMACEUTICALS INC | — — | 2.9% | 12.5M | $135.3M |
| 10 | NASDAQ: PVLA PALVELLA THERAPEUTICS INC NE | — — | 2.9% | 882K | $134.8M |
| 11 | NASDAQ: BBIO BRIDGEBIO PHARMA INC | — — | 2.5% | 1.5M | $115.3M |
| 12 | NASDAQ: IRON DISC MEDICINE INC | — — | 2.2% | 1.4M | $99.1M |
| 13 | NASDAQ: CYTK CYTOKINETICS INC | — — | 2.2% | 1.2M | $98.8M |
| 14 | NASDAQ: DYN DYNE THERAPEUTICS INC | — — | 1.5% | 3.2M | $70.0M |
| 15 | NASDAQ: ASND ASCENDIS PHARMA A/S | — — | 1.3% | 225K | $60.1M |
| 16 | NASDAQ: SVRA SAVARA INC | — — | 1.3% | 9.7M | $59.9M |
| 17 | NASDAQ: PBLS PARABILIS MEDICINES INC | — — | 1.1% | 1.9M | $52.6M |
| 18 | NASDAQ: AURA AURA BIOSCIENCES INC | — — | 1.1% | 7.1M | $50.4M |
| 19 | NASDAQ: ACHV ACHIEVE LIFE SCIENCE INC | — — | 1.1% | 7.6M | $49.7M |
| 20 | NASDAQ: VOR VOR BIOPHARMA INC | — — | 1.0% | 2.5M | $46.8M |
| 21 | NASDAQ: ALLO ALLOGENE THERAPEUTICS INC | — — | 1.0% | 22.4M | $46.7M |
| 22 | NASDAQ: TARS TARSUS PHARMACEUTICALS INC | — — | 1.0% | 729K | $45.9M |
| 23 | NASDAQ: BCRX BIOCRYST PHARMACEUTICALS INC | — — | 0.9% | 4.0M | $40.1M |
| 24 | NASDAQ: ALKS ALKERMES PLC | — — | 0.8% | 701K | $36.7M |
| 25 | NASDAQ: ACAD ACADIA PHARMACEUTICALS INC | — — | 0.8% | 1.4M | $36.4M |
Showing 1–25 of 41 positions on this page reported in this 13F.
- Healthcare98%
- AddedNAMSNEWAMSTERDAM PHARMA COMPANY+6.8%$613.0M
- AddedERASERASCA INC+1.2%$457.5M
- AddedMAZEMAZE THERAPEUTICS INC+10.2%$150.2M
- AddedASNDASCENDIS PHARMA A/S+68.9%$60.1M
- NewPBLSPARABILIS MEDICINES INC—$52.6M
- AddedAURAAURA BIOSCIENCES INC+39.2%$50.4M
- NewACHVACHIEVE LIFE SCIENCE INC—$49.7M
- AddedALLOALLOGENE THERAPEUTICS INC+491%$46.7M
- AddedMNKDMANNKIND CORP+11.9%$28.1M
- NewDSGNDESIGN THERAPEUTICS INC—$26.2M
- ReducedTRVITREVI THERAPEUTICS INC−0.0%$185.4M
- ReducedBBIOBRIDGEBIO PHARMA INC−55.1%$115.3M
- SoldKALVKALVISTA PHARMACEUTICALS INC−100%—
- SoldRVMDREVOLUTION MEDICINES INC−100%—
- SoldAGIOAGIOS PHARMACEUTICALS INC−100%—
Reading Frazier Life Sciences Management, L.P.’s 13F portfolio
Frazier Life Sciences Management, L.P.’s $4.6B 13F book is spread across 41 reported positions and is highly concentrated — its ten largest positions alone are 74% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are MIRM, NAMS, ERAS, MBX and ARQT, led by MIRUM PHARMACEUTICALS INC (MIRM) at 20% of the portfolio. The heaviest sector exposure is Healthcare (98%).
What Frazier Life Sciences Management, L.P. changed last quarter
Between 2026-03-31 and Q2 2026, Frazier Life Sciences Management, L.P. was a net buyer: it opened 6 new positions and added to 8 more, while trimming 2 and closing 3 outright. Against a 41-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was NEWAMSTERDAM PHARMA COMPANY (NAMS), and its biggest reduction was TREVI THERAPEUTICS INC (TRVI).
What a 13F does and doesn’t reveal
A 13F captures only Frazier Life Sciences Management, L.P.’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Frazier Life Sciences Management, L.P. is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Frazier Life Sciences Management, L.P.'s profile on this page is built directly from those filings.
How current is the 13F data on Frazier Life Sciences Management, L.P.'s page?
It reflects Frazier Life Sciences Management, L.P.'s most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Frazier Life Sciences Management, L.P. files its next quarterly report, this page refreshes automatically.
Can I see Frazier Life Sciences Management, L.P.'s complete list of holdings?
This page highlights Frazier Life Sciences Management, L.P.'s largest positions rather than all 41 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Frazier Life Sciences Management, L.P.'s filings.
Does a 13F show everything Frazier Life Sciences Management, L.P. owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Frazier Life Sciences Management, L.P.'s book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Frazier Life Sciences Management, L.P. made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

